Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December
President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' journey of 25 years in drug development.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
​
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
​
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
​
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square